Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 25 |
| List of Tables | 22 | 4 |
| List of Figures | 26 | 1 |
| Introduction | 27 | 1 |
| Global Markets Direct Report Coverage | 27 | 1 |
| Bladder Cancer Overview | 28 | 1 |
| Therapeutics Development | 29 | 2 |
| Pipeline Products for Bladder Cancer Overview | 29 | 1 |
| Pipeline Products for Bladder Cancer Comparative Analysis | 30 | 1 |
| Bladder Cancer Therapeutics under Development by Companies | 31 | 8 |
| Bladder Cancer Therapeutics under Investigation by Universities/Institutes | 39 | 1 |
| Bladder Cancer Pipeline Products Glance | 40 | 3 |
| Late Stage Products | 40 | 1 |
| Clinical Stage Products | 41 | 1 |
| Early Stage Products | 42 | 1 |
| Bladder Cancer Products under Development by Companies | 43 | 11 |
| Bladder Cancer Products under Investigation by Universities/Institutes | 54 | 1 |
| Bladder Cancer Companies Involved in Therapeutics Development | 55 | 109 |
| 4SC AG | 55 | 1 |
| Adaptimmune Therapeutics Plc | 56 | 1 |
| ADC Therapeutics SA | 57 | 1 |
| Agenus Inc | 58 | 1 |
| Altor BioScience Corporation | 59 | 1 |
| AndroScience Corporation | 60 | 1 |
| APIM Therapeutics AS | 61 | 1 |
| Arno Therapeutics, Inc. | 62 | 1 |
| Astellas Pharma Inc. | 63 | 1 |
| Astex Pharmaceuticals Inc | 64 | 1 |
| Aura Biosciences, Inc. | 65 | 1 |
| AVEO Pharmaceuticals, Inc. | 66 | 1 |
| Azaya Therapeutics, Inc. | 67 | 1 |
| Bavarian Nordic A/S | 68 | 1 |
| Bayer AG | 69 | 1 |
| BioCancell Ltd | 70 | 1 |
| Biomics Biotechnologies Co., Ltd. | 71 | 1 |
| Bioncotech Therapeutics SL | 72 | 1 |
| Biotest AG | 73 | 1 |
| Boehringer Ingelheim GmbH | 74 | 1 |
| Bristol-Myers Squibb Company | 75 | 1 |
| Celgene Corporation | 76 | 1 |
| Cellceutix Corporation | 77 | 1 |
| Celldex Therapeutics, Inc. | 78 | 1 |
| Celprogen, Inc. | 79 | 1 |
| Celsion Corporation | 80 | 1 |
| Codagenix, Inc. | 81 | 1 |
| Cold Genesys, Inc. | 82 | 1 |
| Corvus Pharmaceuticals Inc | 83 | 1 |
| CytomX Therapeutics, Inc. | 84 | 1 |
| DormaTarg, Inc. | 85 | 1 |
| Eisai Co., Ltd. | 86 | 1 |
| Eleven Biotherapeutics Inc. | 87 | 1 |
| Eli Lilly and Company | 88 | 1 |
| Elsalys Biotech SAS | 89 | 1 |
| enGene, Inc | 90 | 1 |
| Esperance Pharmaceuticals, Inc. | 91 | 1 |
| Exelixis, Inc. | 92 | 1 |
| F. Hoffmann-La Roche Ltd. | 93 | 1 |
| Five Prime Therapeutics, Inc. | 94 | 1 |
| Gene Signal International SA | 95 | 1 |
| Genmab A/S | 96 | 1 |
| GlaxoSmithKline Plc | 97 | 1 |
| H3 Biomedicine Inc. | 98 | 1 |
| Hamlet Pharma AB | 99 | 1 |
| Heat Biologics, Inc. | 100 | 1 |
| HEC Pharm Co., Ltd. | 101 | 1 |
| Hutchison MediPharma Limited | 102 | 1 |
| Idera Pharmaceuticals, Inc. | 103 | 1 |
| ImmuNext, Inc. | 104 | 1 |
| Immunocore Limited | 105 | 1 |
| Immunomedics, Inc. | 106 | 1 |
| Immupharma Plc | 107 | 1 |
| InteRNA Technologies B.V. | 108 | 1 |
| Johnson &Johnson | 109 | 1 |
| LipoMedix Pharmaceutical Inc. | 110 | 1 |
| MacroGenics, Inc. | 111 | 1 |
| MaxiVAX SA | 112 | 1 |
| Meabco A/S | 113 | 1 |
| Medicenna Therapeutics, Inc. | 114 | 1 |
| MedImmune LLC | 115 | 1 |
| Merck &Co., Inc. | 116 | 1 |
| Merck KGaA | 117 | 1 |
| Mirati Therapeutics Inc. | 118 | 1 |
| Mirna Therapeutics, Inc. | 119 | 1 |
| Miyarisan Pharmaceutical Company, Ltd | 120 | 1 |
| Moleculin Biotech Inc | 121 | 1 |
| NanoCarrier Co., Ltd. | 122 | 1 |
| Nektar Therapeutics | 123 | 1 |
| NuCana BioMed Limited | 124 | 1 |
| Omeros Corporation | 125 | 1 |
| Oncogenex Pharmaceuticals, Inc. | 126 | 1 |
| Oncolytics Biotech Inc. | 127 | 1 |
| OncoTherapy Science, Inc. | 128 | 1 |
| Ono Pharmaceutical Co., Ltd. | 129 | 1 |
| Optimum Therapeutics, LLC | 130 | 1 |
| Pfizer Inc. | 131 | 1 |
| Pharma Mar, S.A. | 132 | 1 |
| Philogen S.p.A. | 133 | 1 |
| Plexxikon Inc. | 134 | 1 |
| Polaris Pharmaceuticals, Inc. | 135 | 1 |
| Provectus Biopharmaceuticals, Inc. | 136 | 1 |
| PsiOxus Therapeutics Limited | 137 | 1 |
| Rexahn Pharmaceuticals, Inc. | 138 | 1 |
| Rodos BioTarget GmbH | 139 | 1 |
| Sanofi | 140 | 1 |
| Savoy Pharmaceuticals, Inc. | 141 | 1 |
| Serometrix, LLC | 142 | 1 |
| Shionogi &Co., Ltd. | 143 | 1 |
| Sillajen Biotherapeutics | 144 | 1 |
| Sorrento Therapeutics Inc | 145 | 1 |
| Spectrum Pharmaceuticals, Inc. | 146 | 1 |
| Stemline Therapeutics, Inc. | 147 | 1 |
| Sun Pharma Advanced Research Co Ltd | 148 | 1 |
| Synovo GmbH | 149 | 1 |
| Taiwan Liposome Company, Ltd. | 150 | 1 |
| Tara Immuno-Oncology Therapeutics LLC | 151 | 1 |
| Taris Biomedical LLC | 152 | 1 |
| Telormedix SA | 153 | 1 |
| TesoRx Pharma LLC | 154 | 1 |
| Theravectys SA | 155 | 1 |
| Theryte Limited | 156 | 1 |
| Transgene SA | 157 | 1 |
| UroGen Pharmaceuticals, Ltd. | 158 | 1 |
| Vakzine Projekt Management GmbH | 159 | 1 |
| Vault Pharma Inc. | 160 | 1 |
| Vaxeal Holding SA | 161 | 1 |
| Vaxiion Therapeutics, Inc. | 162 | 1 |
| Viralytics Ltd. | 163 | 1 |
| Bladder Cancer Therapeutics Assessment | 164 | 23 |
| Assessment by Monotherapy Products | 164 | 1 |
| Assessment by Combination Products | 165 | 1 |
| Assessment by Target | 166 | 8 |
| Assessment by Mechanism of Action | 174 | 9 |
| Assessment by Route of Administration | 183 | 2 |
| Assessment by Molecule Type | 185 | 2 |
| Drug Profiles | 187 | 526 |
| 4SC-205 Drug Profile | 187 | 2 |
| acalabrutinib Drug Profile | 189 | 3 |
| ADCT-502 Drug Profile | 192 | 1 |
| aganirsen Drug Profile | 193 | 2 |
| ALT-801 Drug Profile | 195 | 2 |
| ALT-803 Drug Profile | 197 | 3 |
| Andes-1537 Drug Profile | 200 | 1 |
| Antisense RNAi Oligonucleotide for Bladder Cancer Drug Profile | 201 | 1 |
| Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer Drug Profile | 202 | 1 |
| Antisense RNAi Oligonucleotides for Bladder Cancer Drug Profile | 203 | 1 |
| Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer Drug Profile | 204 | 2 |
| apatorsen Drug Profile | 206 | 7 |
| apaziquone Drug Profile | 213 | 2 |
| APTA-12 Drug Profile | 215 | 1 |
| AR-42 Drug Profile | 216 | 2 |
| AS15 + recMAGE-A3 Drug Profile | 218 | 1 |
| ASC-JM.Z1 Drug Profile | 219 | 1 |
| ASG-15ME Drug Profile | 220 | 2 |
| atezolizumab Drug Profile | 222 | 14 |
| ATX-101 Drug Profile | 236 | 1 |
| AV-203 Drug Profile | 237 | 3 |
| avelumab Drug Profile | 240 | 6 |
| AZD-1775 + durvalumab Drug Profile | 246 | 1 |
| B-701 Drug Profile | 247 | 1 |
| BAY-1163877 Drug Profile | 248 | 1 |
| BC-819 Drug Profile | 249 | 3 |
| Biologic for Superficial Bladder Cancer Drug Profile | 252 | 1 |
| bladder cancer + pertussis + tuberculosis vaccine Drug Profile | 253 | 1 |
| BMS-986016 Drug Profile | 254 | 1 |
| BO-011 Drug Profile | 255 | 1 |
| BO-110 Drug Profile | 256 | 1 |
| BPC-1 Drug Profile | 257 | 1 |
| BV-2711 Drug Profile | 258 | 1 |
| BVD-723 Drug Profile | 259 | 1 |
| cabozantinib s-malate Drug Profile | 260 | 17 |
| cavatak Drug Profile | 277 | 12 |
| CBM-588 Drug Profile | 289 | 2 |
| CCV-3612653 Drug Profile | 291 | 1 |
| CDX-1401 Drug Profile | 292 | 3 |
| Cellular Immunotherapy for Bladder Cancer Drug Profile | 295 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 296 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 297 | 1 |
| Cellular Immunotherapy to Target HER-2 for Oncology Drug Profile | 298 | 1 |
| Cellular Immunotherapy to Target HER2 for Oncology Drug Profile | 299 | 1 |
| Cellular Immunotherapy to Target MAGE-A10 for Oncology Drug Profile | 300 | 2 |
| CG-0070 Drug Profile | 302 | 2 |
| CG-0070IT Drug Profile | 304 | 1 |
| cisplatin Drug Profile | 305 | 2 |
| CM-24 Drug Profile | 307 | 2 |
| CPI-444 Drug Profile | 309 | 3 |
| CT-053 Drug Profile | 312 | 1 |
| CV-301 Drug Profile | 313 | 2 |
| CX-072 Drug Profile | 315 | 1 |
| DAB-389EGF Drug Profile | 316 | 1 |
| docetaxel Drug Profile | 317 | 2 |
| docetaxel Drug Profile | 319 | 1 |
| doxorubicin Drug Profile | 320 | 15 |
| Drug for Bladder Cancer Drug Profile | 335 | 1 |
| Drug for Multiple Myeloma and Bladder Cancer Drug Profile | 336 | 1 |
| Drug for NMIBC Drug Profile | 337 | 1 |
| Drugs to Inhibit TYRO-3 for Bladder Cancer Drug Profile | 338 | 1 |
| DT-310 Drug Profile | 339 | 1 |
| DT-320 Drug Profile | 340 | 1 |
| DT-330 Drug Profile | 341 | 1 |
| durvalumab Drug Profile | 342 | 11 |
| durvalumab + tremelimumab Drug Profile | 353 | 4 |
| E-7046 Drug Profile | 357 | 1 |
| EF-022 Drug Profile | 358 | 1 |
| emactuzumab Drug Profile | 359 | 1 |
| enadenotucirev Drug Profile | 360 | 4 |
| enfortumab vedotin Drug Profile | 364 | 2 |
| enoblituzumab Drug Profile | 366 | 2 |
| EP-400 Drug Profile | 368 | 1 |
| eribulin mesylate Drug Profile | 369 | 14 |
| erlotinib hydrochloride Drug Profile | 383 | 4 |
| flavokawain A Drug Profile | 387 | 1 |
| FPA-144 Drug Profile | 388 | 3 |
| gemcitabine hydrochloride Drug Profile | 391 | 1 |
| GSK-2849330 Drug Profile | 392 | 1 |
| GSK-3174998 Drug Profile | 393 | 1 |
| GSK-3326595 Drug Profile | 394 | 1 |
| guadecitabine Drug Profile | 395 | 7 |
| Hamlet Drug Profile | 402 | 1 |
| HMPL-453 Drug Profile | 403 | 1 |
| ICT-2700 Drug Profile | 404 | 1 |
| imiquimod Drug Profile | 405 | 2 |
| IMO-2055 Drug Profile | 407 | 2 |
| indatuximab ravtansine Drug Profile | 409 | 3 |
| IPP-204106 Drug Profile | 412 | 2 |
| JAAF-11 Drug Profile | 414 | 1 |
| JNJ-63723283 Drug Profile | 415 | 1 |
| JNJ-64457107 Drug Profile | 416 | 2 |
| Kevetrin Drug Profile | 418 | 11 |
| lenalidomide Drug Profile | 429 | 14 |
| LPMX-2 Drug Profile | 443 | 1 |
| lurbinectedin Drug Profile | 444 | 7 |
| LY-3076226 Drug Profile | 451 | 1 |
| MDNA-55 Drug Profile | 452 | 1 |
| MFA-370 Drug Profile | 453 | 1 |
| MGD-009 Drug Profile | 454 | 2 |
| miR-101 Drug Profile | 456 | 1 |
| mitomycin SR Drug Profile | 457 | 1 |
| MMD-37K Drug Profile | 458 | 1 |
| mocetinostat Drug Profile | 459 | 5 |
| Monoclonal Antibody to Antagonize EGFR for Superficial Bladder Cancer Drug Profile | 464 | 1 |
| Monoclonal Antibody to Inhibit TYRO-3 for Metastatic Bladder Cancer Drug Profile | 465 | 1 |
| Monoclonal Antibody to Target CEACAM-1 for Oncology Drug Profile | 466 | 1 |
| MTG-201 Drug Profile | 467 | 2 |
| MVXONCO-1 Drug Profile | 469 | 2 |
| NEO-PV-01 Drug Profile | 471 | 2 |
| nintedanib Drug Profile | 473 | 10 |
| nitroxoline Drug Profile | 483 | 1 |
| nivolumab Drug Profile | 484 | 33 |
| NKTR-214 Drug Profile | 517 | 3 |
| NUC-1031 Drug Profile | 520 | 3 |